About
Us
Leadership Team
Board of Directors
Advisory Board
Clinical
Trials
TIGeR-PaC
Candidate Criteria
TIGeR-PaC Participating
Clinical Sites
Our Therapy
Platform
Pipeline
Overview
For
Clinicians
in the
News
Investors
Contact
Us
For Clinicians
Clinical Data
RenovoCath IFU
Clinical Data
Studies continue to support the therapeutic method of the RenovoTAMP platform for targeted treatment of pancreatic cancer. Following are highlights of clinical data from publications, abstracts, and medical conference presentations.
*
Validating and Optimizing Trans Arterial Micro Perfusion Using a Novel Double Balloon Catheter in a Pig Model for Local Delivery of Chemotherapy to Solid Tumors.
Presented at SIR 2021 Annual Scientific Meeting
, March 20-26,2021
Sepsis and pancreatic cancer: Biliary stents a significant risk factor in patients undergoing chemotherapy.
Presented at 2021 ASCO Gastrointestinal Cancers Symposium
, January 15-17, 2021
Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.
Presented at 2021 ASCO Gastrointestinal Cancers Symposium
, January 15-17, 2021
Trans Arterial Chemotherapy for Treatment of Locally Advanced Pancreatic Cancer: Treatment Factors Impacting Survival.
Presented at SIR 2020 Virtual
, June 13-14, 2020
Targeted Intra-Arterial Gemcitabine: Impact on Survival in Patients with Locally Advanced Pancreatic Cancer –A New Treatment Paradigm.
Presented at the World Congress on Pancreatic Cancer & Liver Diseases
, October 23, 2019
Management of Advanced Stage Hepatocellular Carcinoma with Extensive Portal Vein Tumor Thrombus Using an Adjustable Dual Balloon Occlusion Technique.
Published in Journal of Vascular and Interventional Radiology
, July, 2019
Localized Intra-arterial Gemcitabine: Impact on Survival in Patients with LAPC – a New Treatment Paradigm.
Presented at Pancreas Club Annual Meeting
, May 18, 2019
New Experience with Transarterial Micro-Perfusion (TAMP).
Presented at GEST 2019
, May 11, 2019
Treatment of Hepatic Tumors with Inaccessible Vasculature Using an Adjustable Length Dual Occlusion Balloon Catheter System.
Journal of Vascular & Interventional Radiology
, September 2018
Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma.
Journal of Pancreatic Cancer
, August 2017
Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors.
Presented at AHPBA Annual Meeting
, April 2, 2017
Treatment of Hepatic Tumors with Inaccessible Vasculature Using an Adjustable Length Dual Occlusion
Pancreatic Cancer: Chemoembolization Using A Double Balloon Catheter.
Presented at AIM Symposium
, November 14, 2016
Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors.
Poster presented to 50th Annual Pancreas Club Meeting
, May 20-21, 2016
Pancreas Club Abstract
: Is Intra-Arterial with Targeted Delivery of Gemcitabine Safe in Treatment of Patients with Loco-Regional Pancreatic Tumors?
May 20-21, 2016
IHPBA 2016 Abstract
: Intra-arterial and Tumor-Targeted Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer,
April 20-23, 2016
RenovoCath IFU
RenovoRx product Instructions For Use (IFU) include:
Trans-Arterial Micro Perfusion (TAMP): RenovoCath – ENGLISH
Trans-Arterial Micro Perfusion (TAMP): RenovoCath – DUTCH
Trans-Arterial Micro Perfusion (TAMP): RenovoCath – FRENCH
Trans-Arterial Micro Perfusion (TAMP): RenovoCath – GERMAN
* RenovoTAMP is currently under investigation in the United States.
Menu
